Business Context and Reporting Period
This Form 8-K is filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on March 4, 2025. The report details a material corporate action: a 1-for-17 reverse stock split of the Company's common stock. The action is intended to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
Key Financial Metrics
This filing is a current report regarding a capital structure change and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split: The Board approved a 1-for-17 reverse split, effective March 7, 2025.
- Nasdaq Compliance Status: The Company previously failed to meet the $1.00 minimum bid price requirement by the December 26, 2024 deadline and was ineligible for a second 180-day remediation period due to insufficient stockholders' equity.
- Delisting Hearing: The Company requested and received a hearing before the Nasdaq Hearings Panel, held on February 18, 2025. A decision is pending.
- Capitalization Adjustment: All outstanding preferred stock, options, warrants, and convertible securities will be adjusted proportionally (share count divided by 17, exercise/conversion price multiplied by 17).
Guidance, Outlook, and Risks
Management Commentary: Management believes the reverse split will increase the closing bid price above $1.00, enabling the Company to maintain its Nasdaq listing. However, the filing explicitly states that no assurances can be provided regarding the effectiveness of the split or the ability to maintain the listing.
Risks and Contingencies:
- Delisting Risk: If the reverse split does not result in compliance, the Company's securities remain subject to suspension or delisting pending the Hearings Panel's decision.
- Fractional Shares: No fractional shares will be issued; instead, they will be rounded up to the nearest whole share, which may result in minor dilution.
- Forward-Looking Statements: Actual results may differ from projections due to risks outlined in the Company's Form 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the effective date of the reverse split (March 7, 2025) and the new CUSIP number (888705308).
- Confirm the outcome of the Nasdaq Hearings Panel decision following the February 18, 2025 hearing.
- Review the Company's most recent Form 10-K or 10-Q to assess stockholders' equity levels, as the Company previously failed the $4,000,000/$5,000,000 equity requirement.
- Monitor the post-split trading price to ensure it sustains the $1.00 minimum bid price requirement.
- Check broker-specific procedures for the automatic adjustment of fractional shares and the rounding-up mechanism.